Article Text
Statistics from Altmetric.com
We thank Drs Jenkins and Beasley for their comments in the recent editorial regarding tiotropium (SPIRIVA).1 Preceding the Singh et al 2 analysis cited by the authors, Boehringer Ingelheim (BI) had analysed both the tiotropium HandiHaler and Respimat pooled datasets using patient-level data on-treatment as well as including vital status. The results showed a nominally statistically significant reduction for tiotropium HandiHaler and a numerical increase with tiotropium Respimat compared with the respective placebo group for all-cause mortality.
These results are adequately reflected in the local SPIRIVA product information (http://www.medicines.org.uk/EMC/searchresults.aspx?term=spiriva&searchtype=QuickSearch) …
Footnotes
-
Contributors All authors conceived, drafted, read and approved the letter.
-
Funding Boehringer Ingelheim Pharma GmbH & Co KG.
-
Competing interests None.
-
Patient consent Obtained.
-
Provenance and peer review Not commissioned; internally peer reviewed.
Linked Articles
- PostScript